Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Masaaki Takamura"'
Autor:
Naruhiro Kimura, Toru Setsu, Yoshihisa Arao, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Akihiko Osaki, Kentarou Igarashi, Nobuo Waguri, Masahiko Yanagi, Toru Takahashi, Soichi Sugitani, Yuka Kobayashi, Masaaki Takamura, Akira Yoshikawa, Toru Ishikawa, Toshiaki Yoshida, Toshiaki Watanabe, Hitoshi Bannai, Tomoyuki Kubota, Kazuhiro Funakoshi, Hiroto Wakabayashi, So Kurita, Norio Ogata, Masashi Watanabe, Yuhsaku Mita, Shigeki Mori, Motoya Sugiyama, Toru Miyajima, Sumio Takahashi, Shuichi Sato, Kisei Ishizuka, Hironobu Ohta, Yutaka Aoyagi, Shuji Terai
Publikováno v:
JGH Open, Vol 6, Iss 8, Pp 577-586 (2022)
Abstract Background and Aim Symptoms of primary biliary cholangitis (PBC) frequently impair one's quality of life (QOL). Nonetheless, with improved treatment, the prognosis of PBC also improves. QOL plays an important role in patients with PBC. In th
Externí odkaz:
https://doaj.org/article/00155ff6b17b4c6ea105600566ce3d49
Autor:
Takahiro Iwasawa, Shunsuke Nojiri, Atsunori Tsuchiya, Suguru Takeuchi, Takayuki Watanabe, Masahiro Ogawa, Satoko Motegi, Takeki Sato, Masaru Kumagai, Taiki Nakaya, Katsuya Ohbuchi, Miwa Nahata, Naoki Fujitsuka, Masaaki Takamura, Shuji Terai
Publikováno v:
Regenerative Therapy, Vol 18, Iss , Pp 231-241 (2021)
Background: Liver cirrhosis is an end-stage multiple liver disease. Mesenchymal stem cells (MSCs) are an attractive cell source for reducing liver damage and regressing fibrosis; additional therapies accompanying MSCs can potentially enhance their th
Externí odkaz:
https://doaj.org/article/1656415cb147473db64c3acf63d3718d
Autor:
Shunsuke Nojiri, Atsunori Tsuchiya, Kazuki Natsui, Suguru Takeuchi, Takayuki Watanabe, Yuichi Kojima, Yusuke Watanabe, Hiroteru Kamimura, Masahiro Ogawa, Satoko Motegi, Takahiro Iwasawa, Takeki Sato, Masaru Kumagai, Yui Ishii, Tomomi Kitayama, Yu-Tung Li, Yuya Ouchi, Takashi Shimbo, Masaaki Takamura, Katsuto Tamai, Shuji Terai
Publikováno v:
Inflammation and Regeneration, Vol 41, Iss 1, Pp 1-15 (2021)
Abstract The liver has a high regenerative ability and can induce spontaneous regression of fibrosis when early liver damage occurs; however, these abilities are lost when chronic liver damage results in decompensated cirrhosis. Cell therapies, such
Externí odkaz:
https://doaj.org/article/b12286f4bc7841a399f9b7b2e8ece5b3
Autor:
Nobutaka Takeda, Atsunori Tsuchiya, Kazuki Natsui, Yui Ishii, Yoshihisa Arao, Naruhiro Kimura, Kentaro Tominaga, Suguru Takeuchi, Kazunao Hayashi, Masaaki Takamura, Shuji Terai
Publikováno v:
Case Reports in Gastroenterology, Vol 15, Iss 2, Pp 507-512 (2021)
Focal nodular hyperplasia (FNH) is the second most frequent benign liver tumor, and it is a fiber-rich stiff lesion. Typically, FNH can be diagnosed by imaging without biopsy. However, liver biopsy and diagnostic resection may be required to differen
Externí odkaz:
https://doaj.org/article/ff14aa3a81c94928831df7ab0c971526
Autor:
Suguru Takeuchi, Atsunori Tsuchiya, Takahiro Iwasawa, Shunsuke Nojiri, Takayuki Watanabe, Masahiro Ogawa, Tomoaki Yoshida, Katsunori Fujiki, Yuta Koui, Taketomo Kido, Yusuke Yoshioka, Mayu Fujita, Junichi Kikuta, Tohru Itoh, Masaaki Takamura, Katsuhiko Shirahige, Masaru Ishii, Takahiro Ochiya, Atsushi Miyajima, Shuji Terai
Publikováno v:
npj Regenerative Medicine, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Mesenchymal stromal cells (MSCs) are used for ameliorating liver fibrosis and aiding liver regeneration after cirrhosis; Here, we analyzed the therapeutic potential of small extracellular vesicles (sEVs) derived from interferon-γ (IFN-γ) p
Externí odkaz:
https://doaj.org/article/ade7176a775045be931db93405b53155
Autor:
Kenya Kamimura, Takeshi Suda, Yasuo Fukuhara, Shujiro Okuda, Yu Watanabe, Takeshi Yokoo, Akihiko Osaki, Nobuo Waguri, Toru Ishikawa, Toshihiro Sato, Yutaka Aoyagi, Masaaki Takamura, Toshifumi Wakai, Shuji Terai
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract Cisplatin (CDDP) is one of the chemotherapeutic drugs being used to treat various cancers. Although effective in many cases, as high doses of CDDP cause cytotoxic effects that may worsen patients’ condition, therefore, a marker of sensitiv
Externí odkaz:
https://doaj.org/article/79557776ef4640ec831b2db676818deb
Autor:
Masahiro Ogawa, Atsunori Tsuchiya, Takayuki Watanabe, Toru Setsu, Naruhiro Kimura, Masato Matsuda, Yoshiki Hoshiyama, Hiroaki Saito, Tsutomu Kanazawa, Motoi Shiotani, Tatsuhiko Sato, Takuya Yagi, Koji Igarashi, Norihiko Yoshimura, Masaaki Takamura, Hidefumi Aoyama, Shuji Terai
Publikováno v:
JGH Open, Vol 4, Iss 5, Pp 827-837 (2020)
Abstract Background and Aim Considering the increasing prevalence of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis (NASH), the development of an effective screening and follow‐up system that enables the recognition of etio
Externí odkaz:
https://doaj.org/article/3dd71008c1294f38ae4a9b3e21826fea
Autor:
Kunihiko Yokoyama, Akira Sakamaki, Kazuya Takahashi, Takumi Naruse, Chihiro Sato, Yuzo Kawata, Kentaro Tominaga, Hiroyuki Abe, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai
Publikováno v:
PLoS ONE, Vol 17, Iss 2, p e0264459 (2022)
Overt hepatic encephalopathy (HE) is one of the complications of liver cirrhosis (LC), which negatively affects the prognosis and quality of life of patients. Small intestinal bacterial overgrowth (SIBO) is significantly associated with LC and its co
Externí odkaz:
https://doaj.org/article/692f7490c69c454286b84b8b7e0e2056
Autor:
Akira Sakamaki, Masaaki Takamura, Norihiro Sakai, Yusuke Watanabe, Yoshihisa Arao, Naruhiro Kimura, Toru Setsu, Hiroyuki Abe, Takeshi Yokoo, Hiroteru Kamimura, Shunsuke Tsubata, Nobuo Waguri, Toru Ishikawa, Hirokazu Kawai, Soichi Sugitani, Tomomi Sato, Kazuhiro Funakoshi, Masashi Watanabe, Kentarou Igarashi, Kenya Kamimura, Atsunori Tsuchiya, Yutaka Aoyagi, Shuji Terai
Publikováno v:
PLoS ONE, Vol 17, Iss 2, p e0263464 (2022)
Due to the developments in the treatment for hepatitis, it is possible to prevent the progression of liver fibrosis and improve patients' prognosis even if it has already led to liver cirrhosis (LC). Consequently, a two-step study was conducted. To b
Externí odkaz:
https://doaj.org/article/8a6311bc1dd14a26a74fee6f948e59ea
Autor:
Takayuki Watanabe, Atsunori Tsuchiya, Suguru Takeuchi, Shunsuke Nojiri, Tomoaki Yoshida, Masahiro Ogawa, Michiko Itoh, Masaaki Takamura, Takayoshi Suganami, Yoshihiro Ogawa, Shuji Terai
Publikováno v:
Regenerative Therapy, Vol 14, Iss , Pp 252-261 (2020)
Introduction: Currently, there are no approved drugs for treating non-alcoholic steatohepatitis (NASH); however, mesenchymal stem cells (MSCs) and their small extracellular vesicles (sEVs), which possess immunomodulatory activities, are potential can
Externí odkaz:
https://doaj.org/article/6607854cb2f4474e85ae67ab042f51ae